Autoimmune Disorder that Affects the Central Nervous System

Anil Ramineni^*
*Correspondence: Anil Ramineni, Department of Neurology, Columbia University, New York, USA, Email:

Introduction

Antibodies to brain-type creatine kinase are a rare autoimmune disorder that affects the central nervous system. Creatine kinase is an enzyme that is found in cells throughout the body and is involved in the production of energy. There are three types of creatine kinase, with the brain-specific type being CK-BB. In this article, we will explore the causes, symptoms, diagnosis, and treatment of antibodies to brain-type creatine kinase. The exact cause of antibodies to brain-type creatine kinase is not fully understood. However, it is believed that the disorder is caused by an autoimmune reaction, where the immune system mistakenly attacks healthy cells in the CNS. This autoimmune reaction can be triggered by a number of factors, including viral infections, exposure to toxins, or a genetic predisposition to autoimmune disorders. The symptoms of antibodies to brain-type creatine kinase can vary depending on the individual and the severity of the disorder. Some of the most common symptoms of antibodies to CK-BB include [1].

Description

Individuals with antibodies to CK-BB may experience difficulties with memory, concentration, and other cognitive functions. Movement disorders such as ataxia, tremors, and chorea may occur in individuals with antibodies to CK-BB. Psychiatric symptoms such as depression, anxiety, and psychosis may occur in individuals with antibodies to CK-BB. Other neurological symptoms such as headaches, fatigue, and sensory disturbances may occur in individuals with antibodies to CK-BB. Diagnosing antibodies to brain-type creatine kinase can be challenging, as the symptoms can be similar to other neurological conditions. In addition, the disorder is rare and may not be considered initially. Diagnostic tests that may be used to diagnose antibodies to CK-BB include. Blood tests can be used to detect antibodies to CK-BB. The presence of these antibodies can help confirm the diagnosis of the disorder [2].

Imaging studies such as MRI and CT scans can be used to look for signs of inflammation or damage in the CNS. EEG is a test that can be used to evaluate the electrical activity of the brain. This test can help identify abnormalities that are associated with antibodies to CK-BB. In some cases, a biopsy of the affected tissue may be needed to confirm the diagnosis of antibodies to CK-BB. The treatment of antibodies to brain-type creatine kinase depends on the severity of the symptoms and the individual's response to treatment. In general, the goals of treatment are to control the immune response and to manage the symptoms of the disorder. Some treatment options for antibodies to CK-BB include. Immunosuppressive therapy involves the use of medications to suppress the immune system's response. These medications can help control the autoimmune response that is causing damage to the CNS. IVIG is a treatment that involves the infusion of antibodies from healthy donors [3].

This treatment can help neutralize the antibodies that are attacking the CNS. Plasmapheresis is a treatment that involves removing the plasma from the blood and replacing it with a substitute solution. This treatment can help remove the antibodies. Antibodies to a brain-type creatine kinase are a type of autoimmune antibody that can attack the brain and nervous system. Creatine kinase is an enzyme that plays a crucial role in energy metabolism, particularly in muscle and brain tissue. Anti-BCK antibodies target a specific form of creatine kinase found primarily in the brain, and their presence has been associated with various neurological conditions. In this article, we will explore the function of creatine kinase, the role of anti-BCK antibodies in neurological disease, and potential treatment options. Creatine kinase is an enzyme that is involved in the production and maintenance of high-energy phosphate compounds, such as ATP [4].

ATP is the primary energy source for cells in the body, including those in the brain and nervous system. Creatine kinase is found in high concentrations in tissues that require large amounts of energy, such as muscle and brain tissue. There are three types of creatine kinase enzymes, CK-MB, CK-BB and CK-MM. CK-MB is primarily found in heart muscle, while CK-BB is primarily found in brain tissue. CK-MM is found in skeletal muscle, as well as in heart and brain tissue. Anti-BCK antibodies specifically target the CK-BB form of creatine kinase. Limbic encephalitis is a type of autoimmune encephalitis that affects the limbic system of the brain, which is involved in memory and emotion. The presence of anti-BCK antibodies has been found in some individuals with limbic encephalitis. Autoimmune epilepsy is a type of epilepsy that is caused by an autoimmune response in the body. The presence of anti-BCK antibodies has been found in some individuals with autoimmune epilepsy. Steroid-responsive encephalopathy associated with autoimmune thyroiditis SREAT is a type of encephalopathy that is associated with autoimmune thyroiditis [5].

Conclusion

The presence of anti-BCK antibodies has been found in some individuals. Cerebellar ataxia is a neurological condition that affects the cerebellum, the part of the brain that is responsible for balance and coordination. The presence of anti-BCK antibodies has been found in some individuals with cerebellar ataxia. The diagnosis of anti-BCK antibodies involves a combination of clinical evaluation, laboratory tests and imaging studies. A thorough medical history and physical examination are necessary to identify symptoms that may be associated with anti-BCK antibody-related neurological disease. Imaging studies, such as MRI or CT scans, may also be used to evaluate the brain and nervous system for signs of inflammation or damage. The treatment of anti-BCK antibody-related neurological disease depends on the specific condition and the severity of the symptoms. In general, the goals of treatment are to control the autoimmune response, reduce inflammation and manage symptoms.

Acknowledgement

None.

Conflict of Interest

None.

References

1. He, Qianru, Lili Man, Yuhua Ji and Shuqiang Zhang, et al. "Comparative proteomic analysis of differentially expressed proteins between peripheral sensory and motor nerves."J Proteome Res 11 (2012): 3077-3089.

Google Scholar, Crossref, Indexed at

2. Zhao, Wei, Peter Langfelder, Tova Fuller and Jun Dong, et al. "Weighted gene coexpression network analysis: State of the art."J Biopharm Stat 20 (2010): 281-300.

Google Scholar, Crossref, Indexed at

3. Allen, Nicholas M., Sarah Weckhuysen, Kathleen Gorman and Mary D. King, et al. "Genetic potassium channel-associated epilepsies: Clinical review of the Kv family."Eur J Paediatr Neurol 24 (2020): 105-116.

Google Scholar, Crossref, Indexed at

4. Liu, Jiang-Hui, Qing Tang, Xiang-Xia Liu and Jian Qi, et al. "Analysis of transcriptome sequencing of sciatic nerves in Sprague-Dawley rats of different ages."Neural Regen Res 13 (2018): 2182.

Google Scholar, Crossref, Indexed at

5. Qi, Jian, Wei-Ya Wang, Ying-Chun Zhong and Jia-Ming Zhou, et al. "Three-dimensional visualization of the functional fascicular groups of a long-segment peripheral nerve."Neural Regen Res 13 (2018): 1465.

Google Scholar, Crossref, Indexed at